This article is more than 5 years old. Information may no longer be current.
New collaboration looks to bring potential liver cancer, melanoma drug to China
Click Here to Manage Email Alerts
Provectus Biopharmaceuticals, Inc. announced it has signed a Letter of Intent with Boehringer Ingelheim Investment Co. Ltd. in China to collaborate in marketing its potential liver cancer and melanoma drug, PV-10, in mainland China, Hong Kong and Taiwan, according to a press release.
Under the agreement, Boehringer will provide commercial support in regards to product registration with the China FDA, communication preparation, market intelligence and other assistance to Provectus in China to the extent that is within Boehringer’s approved business scope and permissible by Chinese laws, according to the release.
Provectus, in return, will grant Boehringer the first priority to be the exclusive collaborator in China for PV-10, if it the drug is successfully registered and approved by the China FDA.
“We are impressed with the work the management of Provectus and its researchers have done so far in developing PV-10 as a potential treatment option for melanoma and cancers of the liver,” Stephen Doyle, vice president and head of specialty care at Boehringer in China, said in the release. “If successful, we believe that many Chinese patients could benefit from being treated with PV-10. Because of this, and the data generated so far, we are prepared to provide the commercially reasonable support Provectus may need to get PV-10 through the drug development and registration approval process in China.”
The release said the two companies signed the agreement today at the European Society for Medical Oncology World Congress on Gastrointestinal Cancer 2015 in Barcelona.
“We are excited about the potential of PV-10 in China and in commencing a working relationship with Boehringer Ingelheim to bring PV-10 to market there,” Peter Culpepper, chief financial officer and chief operating officer of Provectus, said in the release. “We are confident that Boehringer Ingelheim’s expertise in navigating the regulatory requirements in China will prove beneficial to us, and we are also confident that a commercial collaboration will benefit both companies.”
Disclosures: Doyle reports being employed by Boehringer. Culpepper reports being employed by Provectus.